Drug intelligence / Profile preview

Allermi

Development stage
Unknown
Lead developer
Allermi
Modality
Small Molecules
Administration
Intranasal
01

Overview

Allermi is a personalized, multi-ingredient prescription nasal spray developed by Allermi for the treatment of allergic rhinitis and hay fever. The formulation is customized for each patient and typically contains a combination of up to four active ingredients: triamcinolone acetonide (a corticosteroid), azelastine (an antihistamine), oxymetazoline (a micro-dosed decongestant), and an anticholinergic agent. By targeting multiple pathways—including inflammation, histamine receptors, and adrenergic receptors in the nasal vasculature—Allermi aims to provide comprehensive relief from symptoms such as congestion, sneezing, and rhinorrhea. The product is designed by board-certified allergists to optimize efficacy while minimizing side effects like rebound congestion through precise micro-dosing of the decongestant component.

Brand names
AllermiAllermi Super Spray
02

Targets

GR (Glucocorticoid receptor)ADRA1 (Alpha-1 adrenergic receptor family)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Allermi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allermi.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call